Incontinence News and Research

Latest Incontinence News and Research

FDA grants Mederi 510(k) clearance for new MDRF1 radiofrequency generator

FDA grants Mederi 510(k) clearance for new MDRF1 radiofrequency generator

AMS introduces STEP toolkit to help men with ED and SUI

AMS introduces STEP toolkit to help men with ED and SUI

Insufficient evidence of interstitial brachytherapy's advantages for localized prostate cancer treatment

Insufficient evidence of interstitial brachytherapy's advantages for localized prostate cancer treatment

Negative aspects of prostate cancer screening acceptable

Negative aspects of prostate cancer screening acceptable

Behavioral therapies help improve bladder control in men following prostate cancer surgery

Behavioral therapies help improve bladder control in men following prostate cancer surgery

FemmePharma completes FP 1097 Phase II clinical trial in women with OAB

FemmePharma completes FP 1097 Phase II clinical trial in women with OAB

American Medical Systems fourth quarter sales increase 0.7% to $147.0 million

American Medical Systems fourth quarter sales increase 0.7% to $147.0 million

Pros and cons of weight loss surgery in men and women

Pros and cons of weight loss surgery in men and women

Ventrus closes public offering of common stock

Ventrus closes public offering of common stock

Antares Pharma submits NDA for Anturol Gel in patients with overactive bladder

Antares Pharma submits NDA for Anturol Gel in patients with overactive bladder

Halt Medical presents results of Halt Fibroid Study at NIH Global Fibroid Congress

Halt Medical presents results of Halt Fibroid Study at NIH Global Fibroid Congress

NAFC forms council to establish independent quality standards for incontinence products

NAFC forms council to establish independent quality standards for incontinence products

Recordati, Nymox sign European licensing agreement for BPH investigational drug, NX-1207

Recordati, Nymox sign European licensing agreement for BPH investigational drug, NX-1207

Ventrus prices initial public offering at $6.00 per share

Ventrus prices initial public offering at $6.00 per share

Watson, PregLem enter licensing agreement to develop, market Esmya in the U.S. and Canada

Watson, PregLem enter licensing agreement to develop, market Esmya in the U.S. and Canada

Preliminary results from Phase 1b/2a trial of MediciNova's ibudilast in opioid addicts announced

Preliminary results from Phase 1b/2a trial of MediciNova's ibudilast in opioid addicts announced

Emergent declares one-time cash dividend and regular dividend

Emergent declares one-time cash dividend and regular dividend

FDA Advisory Panel recommends approval of Solesta for bowel incontinence

FDA Advisory Panel recommends approval of Solesta for bowel incontinence

Pennsylvania Patient Safety Advisory for 2010 December focusses on tackling norovirus outbreaks

Pennsylvania Patient Safety Advisory for 2010 December focusses on tackling norovirus outbreaks

New microchip implant enables people with paraplegia to exercise paralysed leg muscles

New microchip implant enables people with paraplegia to exercise paralysed leg muscles

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.